Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.

Kang CM, Hwang HK, Choi SH, Lee WJ.

Surg Oncol. 2013 Jun;22(2):123-31. doi: 10.1016/j.suronc.2013.02.007. Epub 2013 Mar 19. Review.

PMID:
23518243
2.

Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.

Barugola G, Partelli S, Crippa S, Capelli P, D'Onofrio M, Pederzoli P, Falconi M.

Am J Surg. 2012 Feb;203(2):132-9. doi: 10.1016/j.amjsurg.2011.03.008. Epub 2011 Aug 6.

PMID:
21824596
3.

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW.

Ann Surg Oncol. 2011 Mar;18(3):619-27. doi: 10.1245/s10434-010-1456-7. Epub 2011 Jan 7.

PMID:
21213060
4.

Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).

Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, Asbun HJ, Bassi C, B├╝chler M, Charnley RM, Conlon K, Cruz LF, Dervenis C, Fingerhutt A, Friess H, Gouma DJ, Hartwig W, Lillemoe KD, Montorsi M, Neoptolemos JP, Shrikhande SV, Takaori K, Traverso W, Vashist YK, Vollmer C, Yeo CJ, Izbicki JR; International Study Group of Pancreatic Surgery.

Surgery. 2014 Jun;155(6):977-88. doi: 10.1016/j.surg.2014.02.001. Epub 2014 Feb 7.

PMID:
24856119
5.

Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.

Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kinoshita T, Kobayashi T, Mitsunaga S, Nakachi K, Ikeda M.

J Hepatobiliary Pancreat Sci. 2011 Jul;18(4):567-74. doi: 10.1007/s00534-011-0371-z.

PMID:
21331805
6.

The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.

Lee JH, Kang CM, Bang SM, Choi JY, Seong JS, Hwang HK, Choi SH, Lee WJ.

Medicine (Baltimore). 2015 Aug;94(31):e1233. doi: 10.1097/MD.0000000000001233.

7.

The determinant factors of recurrence following resection for ductal pancreatic cancer.

Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A, Salvia R, Bassi C, Pederzoli P.

JOP. 2007 Jan 9;8(1 Suppl):132-40.

8.

Preoperative chemoradiotherapy, surgery and adjuvant therapy for resectable pancreatic cancer.

Eguchi H, Nagano H, Tanemura M, Takeda Y, Marubashi S, Kobayashi S, Kawamoto K, Wada H, Hama N, Akita H, Mori M, Doki Y.

Hepatogastroenterology. 2013 Jun;60(124):904-11. doi: 10.5754/hge12974. Epub 2013 Jan 16.

PMID:
23321032
9.

Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.

Tzeng CW, Fleming JB, Lee JE, Xiao L, Pisters PW, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR, Fogelman DR, Crane CH, Balachandran A, Katz MH.

Ann Surg Oncol. 2012 Jun;19(6):2045-53. doi: 10.1245/s10434-011-2211-4. Epub 2012 Jan 19.

PMID:
22258816
10.

Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.

Cooper AB, Slack R, Fogelman D, Holmes HM, Petzel M, Parker N, Balachandran A, Garg N, Ngo-Huang A, Varadhachary G, Evans DB, Lee JE, Aloia T, Conrad C, Vauthey JN, Fleming JB, Katz MH.

Ann Surg Oncol. 2015 Jul;22(7):2416-23. doi: 10.1245/s10434-014-4285-2. Epub 2014 Dec 18.

PMID:
25519927
11.

Multimodality management of borderline resectable pancreatic adenocarcinoma.

Prakash LR, Katz MHG.

Chin Clin Oncol. 2017 Jun;6(3):27. doi: 10.21037/cco.2017.06.17. Review.

12.

Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.

Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, Balachandran A, Varadhachary GR, Pisters PW, Wang H, Gomez HF, Abbruzzese JL, Fleming JB, Wang H.

Ann Diagn Pathol. 2012 Jan;16(1):29-37. doi: 10.1016/j.anndiagpath.2011.08.005. Epub 2011 Nov 3.

13.

Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.

Schwarz L, Katz MH.

Hematol Oncol Clin North Am. 2015 Aug;29(4):727-40. doi: 10.1016/j.hoc.2015.04.004. Epub 2015 Jun 9. Review.

PMID:
26226907
14.

Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?

Crippa S, Partelli S, Zamboni G, Barugola G, Capelli P, Inama M, Bassi C, Pederzoli P, Falconi M.

Surgery. 2012 Sep;152(3 Suppl 1):S112-9. doi: 10.1016/j.surg.2012.05.017. Epub 2012 Jul 3.

PMID:
22766365
15.

Neoadjuvant therapy for non-metastatic pancreatic ductal adenocarcinoma.

Winner M, Goff SL, Chabot JA.

Semin Oncol. 2015 Feb;42(1):86-97. doi: 10.1053/j.seminoncol.2014.12.008. Epub 2014 Dec 9. Review.

PMID:
25726054
16.

Gemcitabine based neoadjuvant chemoradiotherapy therapy in patients with borderline resectable pancreatic cancer.

Cho IR, Chung MJ, Bang S, Park SW, Chung JB, Song SY, Seong J, Hwang HK, Kang CM, Lee WJ, Park JY.

Pancreatology. 2013 Sep-Oct;13(5):539-43. doi: 10.1016/j.pan.2013.07.064. Epub 2013 Jul 18.

PMID:
24075521
17.

Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.

Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele P, Aglietta M.

Ann Surg Oncol. 2006 Sep;13(9):1201-8. Epub 2006 Sep 6.

18.

Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.

Chandhok NS, Saif MW.

JOP. 2014 Mar 10;15(2):91-4. doi: 10.6092/1590-8577/2303.

19.

Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.

di Sebastiano P, Grottola T, di Mola FF.

Updates Surg. 2016 Sep;68(3):235-239. Epub 2016 Sep 15. Review.

PMID:
27629483
20.

The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes.

Kalimuthu SN, Serra S, Dhani N, Chetty R.

J Clin Pathol. 2016 Jun;69(6):463-71. doi: 10.1136/jclinpath-2016-203604. Epub 2016 Feb 25. Review.

PMID:
26915370

Supplemental Content

Support Center